CASI Pharmaceuticals Q4 EPS $(0.45) Misses $(0.24) Estimate, Sales $6.87M Miss $9.41M Estimate
Portfolio Pulse from Benzinga Newsdesk
CASI Pharmaceuticals reported Q4 losses of $(0.45) per share, missing the $(0.24) estimate, and sales of $6.87M, missing the $9.41M estimate. This represents a significant decrease in performance compared to the same period last year.
March 28, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CASI Pharmaceuticals reported significantly lower than expected Q4 earnings and sales, missing analyst estimates.
Missing both earnings and sales estimates significantly, especially by 87.5% for EPS, indicates a substantial underperformance by CASI Pharmaceuticals. This is likely to negatively impact investor sentiment and could lead to a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100